- Original Research Article
- Open Access
Prediction of minimal encephalopathy in patients with HCV-related cirrhosis using albumin-bilirubin, platelets-albumin-bilirubin score, albumin-bilirubin-platelets grade and ammonia level
Egyptian Liver Journal volume 10, Article number: 8 (2020)
Minimal hepatic encephalopathy (MHE) is a complication of liver cirrhosis causing low quality of life, driving skills and higher traffic violation. The neuro-psychometric tests are the gold standard but difficult clinically and time-consuming. The aim was to assess albumin-bilirubin (ALBI), platelets-albumin-bilirubin (PALBI) score, albumin-bilirubin-platelets (ALBI-PLT) grade and ammonia level as MHE predictors. All the patients (n = 257) underwent critical flicker frequency number connection, serial dotting and digit symbol test for MHE diagnosis (n = 166, 64.6%). Liver function, INR, CBC and arterial ammonia were measured.
There was statistically significant difference (p < 0.05) between MHE patients and those without as regards ammonia (86.59 ± 23.25 vs. 63.56 ± 24.2 μmol/L), ALBI score (−2.13 ± 0.53 vs. −2.49 ± 0.38), PALBI score (−2.33 ± 0.39 vs. −2.55 ± 0.26) and ALBI-PLT (3.98 ± 0.49 vs. 3.70 ± 0.56). Patients with MHE were mainly Child-Pugh B and C and also ALBI grade 2 and 3. For MHE discrimination, ALBI, PALBI, ALBI-PLT and ammonia had the following cutoffs >−2.36 (57.23% sensitivity, 77.78% specificity), >−2.5 (60.84% sensitivity, 67.9% specificity), > 3 (87.35% sensitivity, 27.16% specificity) and > 76.5 (69% sensitivity, 72.5% specificity) respectively (p = 0.001). On comparison of the area under the curve, ALBI is comparable to PALBI (p = 0.245) and ammonia (p = 0.603). The ALBI-PLT is inferior to ALBI (p = 0.018) and ammonia (p = 0.021) but comparable to PALBI (p = 0.281). ALBI (odds = 5.64), PALBI (odds = 7.86), ALBI-PLT (odds = 2.86), ammonia (odds = 1.05), Child-Pugh score (odds = 2.13), MELD (odds = 1.26) are independent predictors of MHE.
ALBI, PALBI and ammonia are clinical useful model for MHE prediction.
Hepatic encephalopathy is simply brain dysfunction owing to acute or chronic liver disease. It is of two types; overt and covert type. Overt type is characterized by bedside characteristic clinical features and does not need sophisticated investigations for diagnosis .
Covert or minimal hepatic encephalopathy (MHE) is characterized by an examination by normal mental and neurological status. It can be diagnosed by sophisticated psychometric tests, e.g., paper-and-pencil psychometric tests, inhibitory control test, critical flicker frequency and the stroop smartphone application [2, 3].
Up to 80% of patients with cirrhosis have MHE. Its presence is associated with poor quality of life, inability to drive, traffic violation and accidents. Within 3 years, ~50% may develop overt hepatic encephalopathy [1, 4].
MHE is commonly found with advanced liver disease, history of overt hepatic encephalopathy, esophageal varices and alcohol abuse as etiology of liver cirrhosis .
Since the MHE investigations are expensive, cumbersome and time-consuming, it is important to select the patients that need to undergo them with high yield.
This study aimed to assess albumin-bilirubin (ALBI), platelets-albumin-bilirubin (PALBI) score, albumin-bilirubin-platelets (ALBI-PLT) grade and ammonia level as noninvasive predictors of MHE.
This study was conducted in National Liver Institute Hospitals, Menoufia University, Egypt. After institutional review board approval, an informed consent was obtained before inclusion in the study.
Our study included 257 patients diagnosed to have HCV-related liver cirrhosis. Full history taking and clinical examination were done. Patients with the following criteria were excluded: non-HCV-related liver cirrhosis as HBV, autoimmune, being illiterate or having visual troubles, recent alcohol use, history or presence of overt hepatic encephalopathy, active infections, within 6 weeks gastrointestinal bleeding, renal impairment, electrolyte disturbances, recent use of psychotropic drugs or drugs improving encephalopathy as lactulose and rifaximin, transjugular intrahepatic portosystemic shunt, hepatocellular carcinoma, recent surgery, congestive heart failure, advanced pulmonary disease and psychiatric diseases.
All patients underwent abdominal ultrasonography, liver function tests, CBC, INR, renal function tests and arterial ammonia measurement.
ALBI  = (log10 bilirubin μmol/L × 0.66) + (albumin g/L × −0.085).
ALBI grades: ALBI I ≤ −2.60, ALBI II > −2.60 to ≤ − 1.39 and ALBI III > −1.39.
PALBI  =(2.02 × log10 bilirubin) + (−0.37 × [log10 bilirubin]2) + (−0.04 × albumin) + (−3.48 × log10 platelets) + (1.01 × [log10 platelets]2).
ALBI-PLT  = sum of the ALBI grade (I–III) to the platelet count grade (I–II). Grade I platelet count = platelets > 150,000/mm3 and Grade II platelet count = platelets ≤ 150,000/mm3. The ALBI PLT range is 2–5.
ALBI score can be calculated online through the following link: https://www.mdcalc.com/albi-albumin-bilirubin-grade-hepatocellular-carcinoma-hcc
Data were statistically analyzed using IBM® SPSS® Statistics® version 21 for Windows (IBM Corporation, North Castle Drive, Armonk, New York, USA) and MedCalc® version 18.2.1 (Seoul, Republic of Korea). Data were expressed as mean ± standard deviation and row percentage for nominal data. All p values are 2 tailed, with values < 0.05 considered statistically significant.
Comparisons between two groups were performed using the Student’s t test for parametric data, and Mann-Whitney test for non-parametric data. CHI-squared test (χ2) and Fisher exact test for categorical data analysis. The receiver operating characteristic (ROC) curve analysis was used for the detection of the cutoff value of the MHE presence. For each cutoff, sensitivity, specificity, positive predictive value and negative predictive value were calculated. The area under the curve (AUC) of different variables was compared using the DeLong tests to assess variable discrimination. Univariate and multivariate binary logistic regression were done for detecting the predictors of MHE.
Our study included 257 patients that were diagnosed to have HCV-related liver cirrhosis. MHE was diagnosed in 64.6% of the patients and the rest (35.4%) were free of MHE.
Patients with MHE compared with those without it (Table 1, p < 0.05) were older (54.61 ± 8.3 vs. 50.42 ± 7.92 years) and were having higher values of serum total bilirubin (1.14 ± 0.73 vs. 0.88 ± 0.25 mg/dL), INR (1.34 ± 0.28 vs. 1.18 ± 0.14), Child-Pugh (CTP) score (6.15 ± 1.62 vs. 5.25 ± 0.7) and MELD score (10.78 ± 4.01 vs. 8.46 ± 3.06). In addition, they had lower values of serum albumin (3.46 ± 0.52 vs. 3.83 ± 0.42 g/dL) and WBCs (5.30 ± 1.3 vs. 5.70 ± 1.36 × 103/μL). Patients with MHE were mainly CTP class B and C and also ALBI grade 2 and 3.
There was statistically significant difference (Table 1 and Figs. 1 and 2, p < 0.05) between MHE patients and those MHE-free patients as regards ammonia (86.59 ± 23.25 vs. 63.56 ± 24.2), ALBI score (−2.13 ± 0.53 vs. −2.49 ± 0.38), PALBI score (−2.33 ± 0.39 vs. −2.55 ± 0.26) and ALBI-PLT (3.98 ± 0.49 vs. 3.70 ± 0.56). Both groups were the same for sex, serum AST, ALT, hemoglobin and platelets (p > 0.05).
By univariate logistic regression analysis, the following variables were associated with the existence of MHE as shown in Table 2 (p < 0.05); age (odds = 1.07, 95% C.I = 1.03–1.1), total bilirubin (odds = 3.69, 95% C.I = 1.65–8.26), ammonia (odds = 1.05, 95% C.I = 1.03–1.07), CTP score (odds = 2.13, 95% C.I = 1.48–3.07), MELD (odds = 1.26, 95% C.I = 1.09–1.44), ALBI (odds = 5.64, 95% C.I = 2.82–11.29), PALBI (odds = 7.86, 95% C.I = 3.08–20.09), ALBI-PLT (odds = 2.86, 95% C.I = 1.65–4.97) but serum albumin was inversely related (odds = 2.86, 95% C.I = 0.10–0.37). On multivariate analysis, only age and ammonia was independently associated with MHE.
As shown in Table 3 and Fig. 3, ALBI cutoff >−2.36 had 57.23% sensitivity, 77.78% specificity, 84.1% PPV and 47% NPV (p = 0.001). PALBI cutoff >−2.5 had 60.84% sensitivity, 67.9% specificity, 79.5% PPV and 45.8% NPV (p = 0.001). ALBI-PLT cutoff > 3 had 87.35% sensitivity, 27.16% specificity, 71.1% PPV and 51.2% NPV (p = 0.001). Ammonia cutoff > 76.5 had 71.69% sensitivity, 72.5% specificity, 91.5% PPV and 38.2% NPV (p = 0.001), CTP cutoff > 5 had 45.8% sensitivity, 85.2% specificity, 86.4%PPV and 43.4% NPV (p = 0.001) and MELD cutoff > 8.2 had 65.9% sensitivity, 73.2% specificity, 85.8% PPV and 39.7% NPV (p = 0.001).
On comparison of the AUC of the studied variables to detect the best one, ALBI is comparable to PALBI (p = 0.245) and ammonia (p = 0.603). PALBI is comparable to ammonia (p = 0.267). ALBI-PLT is inferior to ALBI (p = 0.018) and ammonia (p = 0.021) but comparable to PALBI (p = 0.281).
MHE is a major health problem that is not under the spotlight because the patients look normal. It is catastrophic in many points. It prevents complex activities such as driving and planning a trip and impairs social interaction with poor health-related quality of life. Most patients have sleep troubles, short memory affection, work-related fatigue, poor driving, navigation skills. In addition, 40% of patients may develop falls, fractures with increased need for hospitalization and morbidity. MHE is an employment and socioeconomic burden since 60% of blue-collar workers are unfit to work compared with only 20% of white-collar workers .
MHE diagnosis needs sophisticated tests that may be copyrighted, need educated patients, training of the patients before doing the tests and may be costly . There is an urgent need for a non-sophisticated diagnosis of MHE especially if using routine investigations.
MHE correlates with liver dysfunction so assessing the degree of the liver dysfunction may be an indirect method of MHE diagnosis or suspicion. CTP score is based on 5 variables but 2 of them are subjective.
ALBI,  PALBI  and ALBI-PLT  are models for assessment of the liver condition without subjective bias. They are based on routine simple investigations. They were studied mainly in patients with hepatocellular carcinoma and correlated with survival.
To our knowledge, this is the first study on assessing ALBI, PALBI and ALBI-PLT scores in patients with MHE.
In our study, most of the patients with MHE were mainly CTP B and C. Higher values of CTP, MELD, ALBI, PALBI, ALBI-PLT and ammonia levels were associated with MHE. Most patients were ALBI grade 2 and 3. The ALBI, PALBI, ALBI-PLT and ammonia had the following statistically significant cutoffs; >−2.36 (57.23% sensitivity, 77.78% specificity), >−2.5 (60.84% sensitivity, 67.9% specificity), > 3 (87.35% sensitivity, 27.16% specificity) and > 76.5 (69% sensitivity, 72.5% specificity) respectively (p = 0.001). On comparison of the area under the curve to detect the best one; ALBI, PALBI and ammonia were comparable. ALBI-PLT was inferior to ALBI and ammonia but comparable to PALBI.
ALBI, PALBI, ALBI-PLT, ammonia, Child-Pugh scores were independent predictors of MHE. On multivariate analysis, only age and ammonia level were the only independent predictor of MHE.
Sharma and Sharma 2010  conducted a study on 200 patients; only 82 (41%) patients had MHE. MHE patients had statistically higher CTP score (8.4 ± 2.5 vs. 7.7 ± 2.2), MELD (17.9 ± 5.7 vs. 13.4 ± 4.2) and ammonia (104.8 ± 37.9 vs. 72.5 ± 45.2 μmol/L) that is in agreement with our study.
The incidence of MHE in their study was lower than reported in our study (41% vs. 64.6%). The cutoff values in their study were higher than our cutoff values; CTP (7.5 vs. 5), MELD (15.5 vs. 8.2) and ammonia (84.5 vs. 76.5 μmol/L). This may be ascribed to a small number of CTP C patients in our study.
Limitation of the study
small number of patients, small number of CTP class C patients, single-center experience and need to follow up the patients.
ALBI, PALBI and ammonia are clinical useful tools for the prediction of MHE.
Availability of data and materials
The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.
Area under the curve
Minimal hepatic encephalopathy
Receiver operating characteristic
Vilstrup H, Amodio P, Bajaj J, Cordoba J, Ferenci P, Mullen KD et al (2014) Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study Of Liver Diseases and the European Association for the Study of the Liver. Hepatology 60:715–735
Weissenborn K (2015) Diagnosis of minimal hepatic encephalopathy. J Clin Exp Hepatol 5:S54–SS9
Flamm SL (2015) Covert hepatic encephalopathy. Clin Liver Dis 19:473–485
Agrawal S, Umapathy S, Dhiman RK (2015) Minimal hepatic encephalopathy impairs quality of life. J Clin Exp Hepatol 5:S42–SS8
Groeneweg M, Moerland W, Quero JC, Hop WC, Krabbe PF, Schalm SW (2000) Screening of subclinical hepatic encephalopathy. J Hepatol 32:748–753
Sharma P, Sharma B (2010) Predictors of minimal hepatic encephalopathy in patients with cirrhosis. Saudi J Gastroenterol 16:181–187
Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL et al (2015) Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach—The ALBI Grade. J Clin Oncol 33:550–558
Elshaarawy O, Alkhatib A, Elhelbawy M, Gomaa A, Allam N, Alsebaey A, Rewisha E, Waked I (2019) Validation of modified albumin-bilirubin-TNM score as a prognostic model to evaluate patients with hepatocellular carcinoma. World J Hepatol 11(6):542–552
Chen P-H, Hsieh W-Y, Su C-W, Hou M-C, Wang Y-P, Hsin IF et al (2018) Combination of Albumin-bilirubin grade and platelet to predict compensated patient with hepatocellular carcinoma who do not require endoscopic screening for esophageal varices. Gastrointes Endo
Weissenborn K (2013) Psychometric tests for diagnosing minimal hepatic encephalopathy. Metabolic Brain Dis 28:227–229
Montoliu C, Cauli O, Urios A, ElMlili N, Serra MA, Giner-Duran R et al (2011) 3-Nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis. Am J Gastroenterol 106:1629
Felipo V, Urios A, Valero P, Sánchez M, Serra MA, Pareja I et al (2013) Serum nitrotyrosine and psychometric tests as indicators of impaired fitness to drive in cirrhotic patients with minimal hepatic encephalopathy. Liver Int 33:1478–1489
Montoliu C, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM et al (2009) IL-6 and IL-18 in Blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J Clin Gastroenterol 43:272–279
Ditisheim S, Giostra E, Burkhard PR, Goossens N, Mentha G, Hadengue A et al (2011) A capillary blood ammonia bedside test following glutamine load to improve the diagnosis of hepatic encephalopathy in cirrhosis. BMC Gastroenterol 11:134
Ethics approval and consent to participate
National Liver Institute IRB 00003415. Written consent was obtained from the patients
Consent for publication
The author delares that he/she has no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Alsebaey, A. Prediction of minimal encephalopathy in patients with HCV-related cirrhosis using albumin-bilirubin, platelets-albumin-bilirubin score, albumin-bilirubin-platelets grade and ammonia level. Egypt Liver Journal 10, 8 (2020). https://doi.org/10.1186/s43066-020-0023-6
- Minimal hepatic encephalopathy